| Status | In progress |
| Process | STA pre-2018 |
| ID number | 866 |
Provisional Schedule
| Final appraisal determination | 12 October 2018 - 26 October 2018 |
| Expected publication | 21 November 2018 |
Project Team
| Project lead | Jeremy Powell |
Email enquiries
- If you have any queries please email TACommB@Nice.org.uk
Consultees
| Companies sponsors | Steba Biotech |
| Others | Department of Health |
| NHS England | |
| Welsh Government | |
| Professional groups | Association of Cancer Physicians |
| British Association of Urological Surgeons | |
| British Uro-Oncology Group | |
| Cancer Research UK | |
| Royal College of Physicians | |
| Royal College of Radiologists |
Commentators
| Associated public health groups | Public Health England |
| Public Health Wales | |
| Comparator companies | None |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | Institute of Cancer Research |
| National Cancer Research Institute |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 02 August 2018 | Committee meeting: 2 |
| 02 July 2018 - 23 July 2018 | Appraisal consultation: 1 |
| 06 June 2018 | Committee meeting: 1 |
| 03 January 2018 | Invitation to participate |
| 13 October 2016 | The technology appraisal of padeliporfin for treating localised prostate cancer (ID866) has been delayed at the request of Steba. NICE has agreed to this request because administration of the padeliporfin requires equipment that is currently not available in the NHS. NICE and Steba are exploring how this can be addressed. |
| 02 June 2016 | Draft scope documents |
| 13 May 2016 | Referral |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance